Expert Insights

Sponsored
In this video, Dr Graff talks about how the treatment landscape for CLL has evolved in recent years, especially with the introduction of acalabrutinib.
Sponsored
In this video, Dr Goy discusses recent innovations in the treatment of patients with MCL.
Adam M. Brufsky, MD, PhD, University of Pittsburgh School of Medicine, Magee-Women’s Cancer Program, Comprehensive Breast Cancer Center, UPMC Hillman Cancer Center, discusses "Evolving Strategies in…
Anthony Lucci, MD, University of Texas, MD Anderson Cancer Center, highlights the significant results following the recent study which evaluated the role of modified radical mastectomy (MRM) in…
Sponsored
Michael Morse, MD, FACP, MHS, discusses the role that microsatellite stability (MSS) or microsatellite instability (MSI) plays in metastatic CRC.
Sponsored
Ryan Corcoran, MD, PhD, discusses the characterization of BRAF mutations and the evolving treatment landscape for patients with BRAF/RAS mutations.
At the annual Miami Breast Cancer Conference, Kelly Hunt, MD, discussed the use of neoadjuvant endocrine therapy for patients with breast cancer.
Anees Chagpar, MD, discusses her presentation on neoadjuvant chemo for clinically node-negative (cN0) breast cancer that took place at the annual Miami Breast Cancer Conference.

Interviews

Todd Cohen, MD, highlights how certain patients with prostate cancer may be able to forgo receipt of combined ADT.
Ehab L. Atallah, MD, discusses the findings of a study which looked at outcomes after TKI cessation in patients with CML.
Laura Chow, MD, FRCPC, discusses the clinical significance of the ASCEND-7 trial, which examined the intracranial effects of ceritinib in ALK-positive NSCLC.
Jeffrey Rubnitz, MD, PhD, discusses a study on the safety and activity of venetoclax plus chemo for young patients with heavily relapsed/refractory AML.

Webcasts

Sponsored
In this video, Dr Danilov discusses the use of acalabrutinib as a treatment option for patients with CLL, SLL, and MCL.
Sponsored
In this video, Dr Graff talks about how the treatment landscape for CLL has evolved in recent years, especially with the introduction of acalabrutinib.
Sponsored
In this video, Dr Goy discusses recent innovations in the treatment of patients with MCL.
Adam M. Brufsky, MD, PhD, University of Pittsburgh School of Medicine, Magee-Women’s Cancer Program, Comprehensive Breast Cancer Center, UPMC Hillman Cancer Center, discusses "Evolving Strategies in…

Resources

Detailed information about the presentation, diagnosis, staging, prognosis, and treatment of all types of childhood NHL and lymphoproliferative disease.
Non-Hodgkin lymphoma treatment options include chemotherapy, radiation, targeted therapy, plasmapheresis, surveillance, stem cell transplant, and surgery. Get comprehensive information on Non-Hodgkin…
Chronic myelogenous leukemia treatments include tyrosine kinase inhibitors, high-dose therapy with allogeneic transplantation, and other medications. Get detailed information about chronic…
Breast cancer is the most common cancer in pregnant and postpartum women and occurs in about 1 in 3,000 pregnant women. The average patient is between the ages of 32 years and 38 years. Because many…

Debates and Roundtables

In the third part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss notable advancements in the standard treatment of T-cell lymphoma.
In the second part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss the background, findings, and importance of the ECHELON-2 clinical trial.
In the first part of this roundtable, Steven Horwitz, MD; Alison Moskowitz, MD; and Barbara Pro, MD, discuss the challenges of treating patients with T-cell lymphoma.
In the second installment of this roundtable discussion, experts sat down with Oncology Learning Network to discuss use of liquid biopsies to detect treatment resistance in lung cancer, areas for…
Stay in the know.
OncNet Newsletter